Patents Examined by Alicia L Otton
  • Patent number: 10723706
    Abstract: Compounds represented by Formula I are disclosed herein, wherein R, Ra and R1-R14 are as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: July 28, 2020
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Gerardo Zelmar Lederkremer, Julia Leitman, Hagit Eiger, Daniel Offen, Javier Ganz, Moshe Portnoy
  • Patent number: 10723742
    Abstract: A compound or a salt thereof represented by Formula (I). An LSD1 inhibitor containing the compound or a salt thereof as an active ingredient. A pharmaceutical composition containing the compound or salt thereof. An antitumor agent containing the compound or a salt thereof as an active ingredient.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: July 28, 2020
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Satoshi Yamashita, Takahiro Ogawa, Hideya Komatani
  • Patent number: 10717761
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17?-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17?-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: July 21, 2020
    Assignee: FORENDO PHARMA LTD
    Inventors: Leena Hirvelä, Marjo Hakola, Tero Linnanen, Pasi Koskimies, Camilla Stjernschantz
  • Patent number: 10710989
    Abstract: The present invention provides a method of producing a heterocyclic compound useful as an agent for the prophylaxis and/or treatment of Alzheimer's disease and the like. The present invention relates to a method of producing 1,5-anhydro-2,4-dideoxy-2-(4-fluoro-5-methyl-1-oxo-6-(4-(1H-pyrazol-1-yl)benzyl)-1,3-dihydro-2H-isoindol-2-yl)-L-threo-pentitol or a salt thereof, which comprises reacting 4-fluoro-3-hydroxy-5-methyl-6-[4-(1H-pyrazol-1-yl)benzyl]-2-benzofuran-1(3H)-one or a salt thereof, 3-fluoro-2-formyl-4-methyl-5-[4-(1H-pyrazol-1-yl)benzyl]benzoic acid or a salt thereof, or a mixture thereof, with 2-amino-1,5-anhydro-2,4-dideoxy-L-threo-pentitol.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: July 14, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Makoto Kanematsu, Kazuhisa Ishimoto, Tomoaki Katou
  • Patent number: 10711261
    Abstract: Described herein are compounds and methods for tethering proteins. For example, dimers of Protein X listed in Table 1 are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker. The covalently attached dimers exhibit increased stabilization and can be used to treat neurodegenerative diseases (such as, for example, Parkinson's Disease, ALS, Alzheimer's Disease, Huntington's Disease, Epilepsy, Frontotemporal Dementia, and/or DMD), cancer, autoimmune disease, and/or Celiac disease.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: July 14, 2020
    Assignee: Brandeis University
    Inventors: Jeffrey N. Agar, Joseph Salisbury
  • Patent number: 10703730
    Abstract: The present invention relates to trifluoroacetyl hydrazide compounds and medical uses thereof. The compounds have a structure of the following formula: The compounds showed multifunctional mechanisms, including inhibition of glutamate excitotoxicity, activation of MEF2 transcriptional activity, clearance of free radicals, and promotion of nerve differentiation, and has a better protective effect on cells especially nerve cells. The compound can be used to prepare prophylactic or therapeutic medicaments with cytoprotective effects, for the prevention or treatment of diseases related to glutamate receptor activation, MEF2 disorders or excessive free radicals generation. The diseases include, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson and stroke, and the free radicals related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: July 7, 2020
    Inventors: Yuqiang Wang, Haiyun Chen, Zaijun Zhang, Gaoxiao Zhang, Pei Yu, Yewei Sun, Luchen Shan, Liang Tao
  • Patent number: 10703716
    Abstract: Disclosed herein are antibacterial compounds, pharmaceutical compositions including the antibacterial compounds, and methods of treating bacterial infections using the compounds and compositions.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: July 7, 2020
    Assignee: Wayne State University
    Inventors: Fazlul H. Sarkar, Subhash Padhye, Bernhard Max Biersack, Hossein Salimnia
  • Patent number: 10688113
    Abstract: The disclosure relates to a method of treating or preventing eye pain in a subject in need thereof. The method includes administering a compound of formula (I), R1—NH—CH(R2)—P(?O)(OH)—CH2—C(R3)(R4)—CONH—C(R5)(R6)—COOR7, to the subject.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: June 23, 2020
    Assignee: PHARMALEADS
    Inventors: Hervé Poras, Michel Wurm, Stéphane Melik Parsadaniantz, Annabelle Reaux-Le Goazigo
  • Patent number: 10689408
    Abstract: It is intended to provide a novel bisphosphonic acid compound or a salt thereof which shows a remarkable inhibitory effect on ectopic calcification, and a pharmaceutical composition comprising the same. The present invention provides a bisphosphonic acid compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof: wherein represents a single bond or a double bond; A represents a saturated cyclic hydrocarbon or a saturated heterocyclic ring comprising a sulfur atom or an oxygen atom; and R1 and R2 each independently represent an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an aryloxy group, a haloalkoxy group, a haloalkyl group, a halogen atom or a hydrogen atom.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: June 23, 2020
    Assignee: FUJIYAKUHIN CO., LTD.
    Inventors: Seiichi Kobashi, Yoshinobu Aoyagi, Hiroshige Kato, Ryuko Tokuyama, Naoki Ashizawa, Koichi Ishida, Koji Matsumoto
  • Patent number: 10682339
    Abstract: Embodiments of the current invention include methods and compositions for regulating the activity of hormone receptors.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: June 16, 2020
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Marc Cox, Artem Cherkasov
  • Patent number: 10682345
    Abstract: The disclosure relates to the field of medicine, in particular to the field of veterinary medicine. The disclosure specifically relates to muscarinic antagonists (including long acting muscarinic antagonists (LAMAs)) for the treatment of airway disease, such as pulmonary disease, preferably recurrent airway obstruction (RAO), summer pasture associated obstructive pulmonary disease (SPAOPD), and inflammatory airway disease (IAD) in animals, preferably equines such as horses.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: June 16, 2020
    Inventors: Balazs Albrecht, Michael Aven, Janine Lamar
  • Patent number: 10674722
    Abstract: Antimicrobial and foamable alcoholic compositions, where the compositions include at least about 40 wt. % of a C1-4 alcohol and one or more silane surfactants selected from (1) zwitterionic silane surfactants, (2) polyalkoxylated silane surfactants that contain at least one silane group and at least one polyalkylene oxide chain.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: June 9, 2020
    Assignee: GOJO Industries, Inc.
    Inventors: Evan D. Hillman, Daniel J. Lacks, Mitchell J. Cohen
  • Patent number: 10676433
    Abstract: The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: June 9, 2020
    Assignee: Merck Patent GmbH
    Inventor: Srinivasa R. Karra
  • Patent number: 10662172
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: May 26, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Peter Tai Wah Cheng, Ying Wang, Jun Shi, Shiwei Tao, Jun Li, Lawrence J. Kennedy, Robert F. Kaltenbach, III, Hao Zhang, James R. Corte
  • Patent number: 10653795
    Abstract: The present invention relates to a process for the preparation of a hydrogel-linked prodrug releasing a tag moiety-biologically active moiety conjugate, to a hydrogel-linked prodrug releasing a tag moiety-bio logically active moiety conjugate obtainable by such process, to pharmaceutical compositions comprising said prodrug and their use as a medicament.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: May 19, 2020
    Assignee: Ascendis Pharma A/S
    Inventors: Harald Rau, Nora Kaluza, Ulrich Hersel, Thomas Knappe, Burkhardt Laufer
  • Patent number: 10654879
    Abstract: A compound having formula I that is useful for C?O reduction is provided: wherein: M is a transition metal; X1, X2 are each independently a counterion; and R1, R2, R3 are each independently H, C1-6 alkyl, C6-15 aryl, or C6-15 heteroaryl.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: May 19, 2020
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Sri Narayan, Travis J. Williams, Zhiyao Lu, Debanjan Mitra
  • Patent number: 10654814
    Abstract: A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in therapy, e.g. in the treatment of autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: May 19, 2020
    Assignee: KANCERA AB
    Inventors: Kristin Hammer, Mattias Jönsson, Lars Krüger
  • Patent number: 10647685
    Abstract: The present invention relates to a 6-phenoxypyrimidine derivative, a method for preparing the compound and a pharmaceutical composition containing the compound as an active ingredient. Because the 6-phenoxypyrimidine compound represented by Chemical Formula 1 according to the present invention has an activity of inhibiting the production of nitric oxide (NO) as an inflammation-related factor, it is useful in treating and preventing inflammatory diseases including immunological diseases.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: May 12, 2020
    Assignee: Korea Institute of Science and Technology
    Inventors: Eun Joo Roh, Karam Mohamed Hasan Fara Ahmed, So Ra Paik, Woo Young Hur, Elkamhawy Ahmed
  • Patent number: 10640498
    Abstract: The present invention relates to novel compounds of formula (I) and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and in the treatment of cancer.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: May 5, 2020
    Assignee: MISSION THERAPEUTICS LIMITED
    Inventors: Karl Richard Gibson, Alison Jones, Mark Ian Kemp, Andrew Madin, Martin Lee Stockley, Gavin Alistair Whitlock, Michael D. Woodrow
  • Patent number: 10633352
    Abstract: A process for preparing, 1,1,3-Trioxo-1,2-benzothiazole-6-carboxamide of formula (I) comprising: reacting 2-chloro-sulfonyl-terephthalic acid dialkyl ester of formula (II) with ammonia (N H3) or ammonium containing-salt; wherein R represents a branched or non-branched C1-C12 alkyl.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: April 28, 2020
    Assignee: ADAMA AGAN LTD.
    Inventors: Avihai Yacovan, Yaniv Barda, Sima Mirilashvili, Shmuel A. Baron